<SEC-DOCUMENT>0001213900-21-010125.txt : 20210217
<SEC-HEADER>0001213900-21-010125.hdr.sgml : 20210217
<ACCEPTANCE-DATETIME>20210217170944
ACCESSION NUMBER:		0001213900-21-010125
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210217
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210217
DATE AS OF CHANGE:		20210217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alpha Healthcare Acquisition Corp.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		21645983

	BUSINESS ADDRESS:	
		STREET 1:		1177 AVENUE OF THE AMERICAS 5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
		BUSINESS PHONE:		6463213444

	MAIL ADDRESS:	
		STREET 1:		1177 AVENUE OF THE AMERICAS 5TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10105
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea135919-8k_alphahealth.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
February 17, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ALPHA HEALTHCARE ACQUISITION CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-39532</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>85-1763759</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(State or other jurisdiction<BR>
of incorporation)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(I.R.S. Employer <BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1177 Avenue of the Americas,&nbsp;5th
        Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New
        York, New York</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10036</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(646) 494-3296</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Check the appropriate
box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD><TD STYLE="text-align: justify">Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD><TD STYLE="text-align: justify">Pre-commencements communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Title
        of each class</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Trading
        Symbols</B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Name
        of each exchange on which registered</B></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Units, each consisting of one share of Class&nbsp;A Common Stock, and one-half of one Redeemable Warrant</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>AHACU</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Class A Common Stock, par value $0.0001 per share</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>AHAC</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>AHACW</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></TD><TD>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD><TD>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On February 17, 2021, Alpha Healthcare
Acquisition Corp. (&ldquo;AHAC&rdquo;) held an investor webinar (the &ldquo;Webinar&rdquo;) with Humacyte, Inc. (&ldquo;Humacyte&rdquo;)
to discuss the proposed business combination (the &ldquo;Business Combination&rdquo;) between AHAC and Humacyte.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Attached as Exhibit 99.1 to this Current
Report on Form 8-K and incorporated into this Item 7.01 by reference is a transcript of the Webinar. A copy of the Business Combination
Agreement (as it may be amended, supplemented or otherwise modified from time to time, the &ldquo;Business Combination Agreement&rdquo;),
dated February 17, 2021, by and among AHAC, Hunter Merger Sub, Inc. and Humacyte, related to the Business Combination was attached
as Exhibit 2.1 to AHAC&rsquo;s Current Report on Form 8-K filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
on February 17, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The foregoing (including Exhibit 99.1)
is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise be subject to the liabilities of that section, nor will
it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information included under Item 7.01
above is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Important Information About the Merger and Where to Find
It</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A full description of the terms of the Business
Combination will be provided in the registration statement on Form S-4 (the &ldquo;S-4 Registration Statement&rdquo;) to be filed
with the SEC by the Company, which will include a prospectus with respect to the Company&rsquo;s securities to be issued in connection
with the Business Combination and a proxy statement with respect to the stockholder meeting of the Company to vote on the Business
Combination. The Company urges its investors, stockholders and other interested persons to read, when available, the preliminary
proxy statement/prospectus as well as other documents filed with the SEC because these documents will contain important information
about the Company, Humacyte and the Business Combination. After the S-4 Registration Statement is declared effective, the definitive
proxy statement/prospectus to be included in the registration statement will be mailed to stockholders of the Company as of a record
date to be established for voting on the proposed Business Combination. Once available, stockholders will also be able to obtain
a copy of the S-4 Registration Statement, including the proxy statement/prospectus, and other documents filed with the SEC without
charge, by directing a request to: Alpha Healthcare Acquisition Corp., 1177 Avenue of the Americas, 5<SUP>th</SUP>&nbsp;Floor,
New&nbsp;York, New&nbsp;York 10036. The preliminary and definitive proxy statement/prospectus to be included in the S-4 Registration
Statement, once available, can also be obtained, without charge, at the SEC&rsquo;s website (www.sec.gov).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Participants in the Solicitation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company and Humacyte and their respective
directors and executive officers may be considered participants in the solicitation of proxies with respect to the Business Combination
under the rules of the SEC. Information about the directors and executive officers of the Company is set forth in the Company&rsquo;s
final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act on September 17, 2020, and is available free
of charge at the SEC&rsquo;s website at www.sec.gov or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary,
1177 Avenue of the Americas, 5<SUP>th</SUP>&nbsp;Floor, New&nbsp;York, New&nbsp;York 10036. Information regarding the persons who
may, under the rules of the SEC, be deemed participants in the solicitation of the Company&rsquo;s stockholders in connection with
the proposed Business Combination will be set forth in the registration statement containing the proxy statement/prospectus for
the proposed Business Combination when it is filed with the SEC. These documents can be obtained free of charge from the sources
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Current Report contains
forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases,
you can identify forward-looking statements by the following words: &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;ongoing&rdquo; or the negative of these terms
or other comparable terminology, although not all forward-looking statements contain these words. These statements involve
risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be
materially different from the information expressed or implied by these forward-looking statements. Although we believe that
we have a reasonable basis for each forward-looking statement contained in this Current Report, we caution you that these
statements are based on a combination of facts and factors currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this Current Report include, but are not limited to, statements
regarding the proposed Business Combination, including the timing and structure of the Business Combination, the proceeds of
the Business Combination, the initial market capitalization of the combined company following the Closing and the benefits of
the Business Combination, as well as statements about the potential attributes and benefits of Humacyte&rsquo;s product
candidates and the format and timing of Humacyte&rsquo;s product development activities and clinical trials. We cannot assure
you that the forward-looking statements in this Current Report will prove to be accurate. These forward-looking statements
are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from
expected results, including, among others, the ability to complete the Business Combination due to the failure to obtain
approval from the Company&rsquo;s stockholders or satisfy other closing conditions in the Business Combination Agreement, the
occurrence of any event that could give rise to the termination of the Business Combination Agreement, the ability to
recognize the anticipated benefits of the Business Combination, the outcome of any legal proceedings that may be instituted
against the Company or Humacyte following announcement of the proposed Business Combination and related transactions, the
impact of COVID-19 on Humacyte&rsquo;s business and/or the ability of the parties to complete the Business Combination, the
ability to obtain or maintain the listing of the Company&rsquo;s Class A Common Stock on Nasdaq following the proposed
Business Combination, costs related to the proposed Business Combination, changes in applicable laws or regulations, the
possibility that the Company or Humacyte may be adversely affected by other economic, business, and/or competitive factors.
and other risks and uncertainties, including those to be included under the header &ldquo;Risk Factors&rdquo; in the S-4
Registration Statement to be filed by the Company with the SEC and those included under the header &ldquo;Risk Factors&rdquo;
in the final prospectus of the Company related to its initial public offering. Most of these factors are outside the
Company&rsquo;s and Humacyte&rsquo;s control and are difficult to predict. Furthermore, if the forward-looking statements
prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking
statements, you should not regard these statements as a representation or warranty by us or any other person that we will
achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Current
Report represent our views as of the date of this Current Report. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update these forward-looking statements at some point in the
future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not
rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Current
Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>No Offer or Solicitation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Current Report is not a proxy statement
or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination
and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities
in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification
under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting
the requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 10%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit<BR>
Number</B></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 89%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea135919ex99-1_alphahealth.htm"><FONT STYLE="font-size: 10pt">Transcript of Webinar, dated February 17, 2021</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Alpha Healthcare Acquisition Corp.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: February 17, 2021</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Rajiv Shukla</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Rajiv Shukla</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea135919ex99-1_alphahealth.htm
<DESCRIPTION>TRANSCRIPT OF WEBINAR, DATED FEBRUARY 17, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 99.1</B></P>

<P STYLE="margin-right: 0; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-right: 0; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Alpha Healthcare
+ Humacyte</P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Merger Announcement
Presentation Transcription</B></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">February 17, 2021</P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-right: 0; text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-right: 0; width: 100%"><DIV STYLE="margin-right: 0; font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-right: 0; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">RAJIV SHUKLA</P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in; text-align: left"><B>00:00</B></TD><TD STYLE="text-align: left">Hi, this is Rajiv Shukla, of Alpha Healthcare. It&rsquo;s
my pleasure to introduce Humacyte , and the company&rsquo;s founder and CEO, Dr. Laura Niklason. Laura is a well-regarded and
distinguished scientist and biotech executive who is known in the industry for her work on regenerative medicine. She has had
an extensive track record, publishing more than a hundred papers on her work, has been recognized in Fortune and Time Magazine,
and so on for the work that she&rsquo;s done as an innovator and has worked with some of the best scientific minds in building
Humacyte to where it is today.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">My own background in healthcare covers the
last 20 years. I&rsquo;ve had a lot of experience in healthcare M&amp;A at Pfizer, where I led acquisitions for the R&amp;D division
globally, as well as a private equity and hedge fund PM at Morgan Stanley and Citibank. Humacyte , I would say, is by far one of
the most exciting companies that I&rsquo;ve come across and reminds me a fair bit of a previous SPAC transaction with DermTech.
DermTech as of Friday was up nearly 12 fold over the transaction price and represents one of the best performing SPAC deals in
the industry. When I look at Humacyte , there are a number of points that stand out for me that are exciting for both physicians
and patients, as well as for investors. Humacyte is the most advanced and significant player in the bio-engineered human tissue
space. There are other companies that are working on cadaveric tissue or working on animal tissue, such as bovine tissue, or even
on plastic grafts. But there is no other company that I&rsquo;ve come across that is as profoundly impactful as Humacyte in the
work that they&rsquo;re aiming to do.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>02:15</B></TD><TD>If Humacyte is successful, they will impact end markets that are in excess of $150 billion in value, and rack up $12 billion
in peak revenue annually. But once they get to peak revenue figures, in terms of the progress that the company has made in the
private markets, Humacyte is one of the most significant privately funded companies, having raised nearly half a billion dollars
from a lot of very smart investors. One of their biggest investors with a 19% stake is Fresenius Medical Care, which is a leader
in dialysis, as well as in surgical care centers. The company has been recognized as a pioneer by the US FDA, having been granted
the first RMAT designation of any company in the world. RMAT stands for Regenerative Medicine Advanced Therapy, which bolsters
the company&rsquo;s pioneering credentials as being the first of its kind in terms of their progress. Clinically, the company has
initiated multiple phase three clinical trials having collected a lot of very strong phase two data. In addition, the company has
developed in-house manufacturing that can enable them to commercialize their products once they have approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">As you know, biotech manufacturing is a very
critical aspect of success. A lot of companies create tremendous signs and have been tripped up by manufacturing. So the fact that
Humacyte has developed in house manufacturing that can operate at commercial scale is of significant value to patients and providers,
as well as for shareholders. The company has a commercial partnership with Fresenius Medical Care, which is very critical given,
given who Fresenius is and their tremendous footprint in the marketplace. The fact that Fresenius can commercialize homicide&rsquo;s
initial products represents an important de-risking of their plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">Now in terms of the transaction summary and
valuation, we valued Humacyte in two parts. We valued Humacyte on a base valuation of $800 million, which is roughly the same as
their last private round, which involved Fresenius putting in 150 million a couple of years ago, so this is very attractive in
our view. Humacyte has done a lot over the last two years, and the very involvement of Fresenius itself is hugely impactful to
their plans. In order to create an incentive link for management, we&rsquo;ve put together an earn out plan where when the stock
rises by 50%, the company is eligible to receive another seven and a half million shares, and when the stock doubles, they will
receive another seven and a half million shares. And what this effectively represents is a number which is a little below 20% above
their last private round. So it&rsquo;s a very attractive price in our view.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>05:50</B></TD><TD>When we began this process with Humacyte, our initial plan had been to raise a hundred million
dollars in a PIPE, but we had such overwhelming demand from investors for this asset, that we ended up cutting back a lot of great
investors and still ended up with $175 million. That for us is, again, a tremendous validation about our confidence in this company.
After accounting for expenses, we expect that the company will have more than $250 million to fund its future plans. We should
be filing a proxy statement fairly quickly after this announcement, and hence we expect that the transaction should close in the
second quarter of this year. Post-closing the company will be renamed Humacyte, Laura will continue to run the company, and I will
join the Board of the company to support them in whatever way I can. In terms of the transaction terms, I think the key point worth
highlighting is that the company will remain largely held by their insiders. None of the existing inside investors are selling
a single share. In fact, most of the existing insiders are participating in the PIPE, as well as supporting the company in the
public markets. The SPAC shareholders, the public shareholders, will account for 9% and the sponsor will have 2%. So we&rsquo;re
looking at a company that will remain very attractive to the public markets given that they&rsquo;re well capitalized for the near
term plans for the next couple of years, we don&rsquo;t expect Humacyte to need additional funding based on their current plans.
We do expect that in the next couple of years, the company will achieve a number of very important milestones.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>07:48</B></TD><TD>Now, the next quick point worth sharing is what can one expect in terms of public market performance?
When we look at disruptive MedTech companies, companies that have been pioneers in the market, a lot like how Humacyte is a pioneer
in the market, with the first RMAT designation and an extensive product pipeline, we see that disruptive companies have created
an enormous amount of shareholder value and not just in a given segment, but across a number of different medical segments, whether
it is in COPD and sleep or in surgical care through robotics, orthodontics, or in type 1 diabetes, you can see that these companies
have gone up by 30 to 300x since the IPO, and have been tremendously rewarding for shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">The difficult thing of course is to find these
tremendously innovative, disruptive companies. When we look at vascular MedTech companies, we see again, companies that have performed
really well since their IPO and created a lot of shareholder value. Our view is the way one would look at Humacyte is by examining
all of the end markets that they&rsquo;re going to impact, whether it is AV access for dialysis, or it is for peripheral arterial
disease, or it is for coronary arterial bypass grafts, or for type 1 diabetes. If you look at all of these end market areas, these
are huge market opportunities adding up to well north of $150 billion as we discussed earlier. And if you look at the leaders in
these different areas, one can get a sense for how large Humacyte might be, given that they touch all of these areas, they&rsquo;re
not just focused on cardiovascular or on dialysis. So we&rsquo;re very excited about this opportunity and are excited to bring
this to the market on the heels of our DermTech transaction. And with that, I will pass this over to Laura to take you through
the company background. Thank you.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">LAURA NIKLASON</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>10:05</B></TD><TD>My name is Laura Niklason, I&rsquo;m the CEO of Humacyte , and also its founder. I&rsquo;m really
excited to be here with you today and tell you about our clinical-stage company, which has a revolutionary new platform for growing
engineered human tissues at scale. This is really category-defining innovation, and we anticipate that all of our products will
address markets that are greater than $150 billion in size. Markets for our products include vascular disease, heart disease, diabetes,
and lung disease. These tissues are universally implantable, which means that they can turn into the patient&rsquo;s own tissues
over time without any evidence of rejection. Humacyte in its clinical trials has already been saving limbs and saving lives for
patients with severe vascular and kidney disease. If we go to slide 10, you can see some of the investment highlights. This is,
as I mentioned, category-defining innovation that allows patients to regrow their own tissues after implanting one of Humacyte&rsquo;s
products. These tissues become regenerative and are self-healing, and importantly, Humacyte&rsquo;s tissues are available off the
shelf, there&rsquo;s no need to harvest tissues or cells from the patient. We have a deep product pipeline with massive markets,
as mentioned, in peripheral arterial disease and other types of vascular disease in end stage kidney failure and diabetes and vascular
trauma.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">We have extensive clinical data. We&rsquo;ve
been implanting our engineered tissues into patients for over eight years, and we have over 800 patient-years of efficacy and exposure
data. These implants have been done at 60 sites across 6 countries and involve over 430 patients. Importantly, we were the first
product to receive the RMAT designation from the FDA. RMAT stands for Regenerative Medicine Advanced Therapy, and we were the first
technology to receive this designation from the FDA in 2017. Our engineered tissues are manufactured in-house. We&rsquo;ve managed
to bring this production process up to commercial scale. We&rsquo;re a vertically integrated technology company, we manufacture
all of the products that we&rsquo;re studying in our clinical trials. We have a terrific patent portfolio, we have 87 issued patents,
and we have dozens of patents that are currently under evaluation. We also have a deep store of trade secrets and manufacturing
know- how, which really provides a strong barrier to entry for other companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">Importantly, we also have a strategic partnership
with Fresenius Medical Care. Fresenius invested $150 million into Humacyte&rsquo;s technology platform back in 2018. Importantly
Fresenius also has come into our existing pipe investment with this most recent transaction. We&rsquo;ve already partnered with
Fresenius to work with them, to commercialize some of our earliest product applications, including vascular trauma, dialysis access,
and peripheral arterial disease. If we go to slide 11, we can see that Humacyte aims to entirely transform how we practice medicine
across many types of disease. Humacyte is aiming to grow replacement tissues and ultimately organs so that there&rsquo;s no more
waiting to harvest tissues and organs from other individuals or from the patient. We also have shown already in our clinical trials
that we help patients avoid limb loss and amputations due to their vascular disease. Because these tissues are not immunogenic,
our patients need no immunosuppression, so they&rsquo;re not tied to a lifetime of these medicines, and also it&rsquo;s critical
to note that patients will now not need to have tissues and vessels harvested from one part of their body to help revascularize
another part. This is really the next generation of clinical care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>13:55</B></TD><TD>If we go to slide 12, we can see some examples of Humacyte &lsquo;s product pipeline. In the
upper left-hand corner you can see an image of one of Humacyte &lsquo;s HAVs or human cellular vessels, that&rsquo;s implanted
as an arterial venous graft in a patient with kidney failure. After the incisions in this patient are allowed to heal, this patient
went on to use this graft for his dialysis access for a period of many years. The dialysis access application is the one in which
we have the most clinical data, in fact, we&rsquo;ve implanted Humacyte&rsquo;s vessels in over 350 patients for use in dialysis
access. Similarly, we&rsquo;ve also developed earlier stage pipeline products to treat type 1 diabetes. In a modification of Humacyte
&lsquo;s engineered vessel technology, we&rsquo;ve developed methods to put pancreatic islets, which are the cells from your pancreas
that secrete insulin around the outside of our HAV. What we envision one day is being able to do an HAV implant, similar to what
you see in the upper left, but in this case, having the implant be coated with islets from the pancreas. In patients with type
one diabetes this type of implant may one day be able to effectively reverse their diabetes and render a cure.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">Also in our pipeline, we&rsquo;re studying the
use of these engineered vessels for coronary artery bypass. In the lower left you can see an image of a large animal heart that&rsquo;s
been bypassed with an engineered vessel that was grown in Humacyte &lsquo;s facility. This is part of a trial in large animals
to gain data that we&rsquo;ll submit to the FDA in order to gain approval for a phase one trial in heart bypass in humans. The
markets that are potentially addressed by Humacyte&rsquo;s products are enormous. For the products in which we&rsquo;re already
in clinical trials, those end markets approach $20 billion. Furthermore, for coronary artery bypass, the size of that market approach
is $70 billion. For our nonvascular products, which are also in Humacyte&rsquo;s, pipeline, such as replacement tracheas, lungs,
and esophagus, there are also massive markets on the order of $70 billion. So Humacyte is really not a one trick pony. Humacyte
has multiple products that are tee&rsquo;d up for commercialization in the next few years, and then along and deep pipeline to
address many types of human disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>16:20</B></TD><TD>If we go to slide 14, you can get a sense of what our anticipated product rollout looks like.
We expect in 2023 to launch our first product application, which is using the HAV to treat patients with acute vascular injuries,
such as might be experienced in a car accident, or in an industrial accident. Phase three trials are underway in this application
right now, and we expect to finish enrolling our phase three trauma trial in 2022. Given that timeline, we anticipate gaining approval
for that product in 2023. Following shortly on the heels of the trauma application, we expect to complete enrollment of our phase
three trials and dialysis access in 2021. The follow-up of those patients should be completed in 2022, and filing with the FDA
we would anticipate would give us product approval sometime in 2023. Thereafter, we anticipate evaluating peripheral arterial disease
as a product. We&rsquo;ve already completed our phase two trials and PAD, and we&rsquo;re currently designing a phase three trial,
which we anticipate would gain us approval sometime around 2025.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.55pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">Going to slide 15, you can see what our manufacturing
process looks like.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">We start with cells that are harvested from
human blood vessels. These cells are actually taken from organ donors for whom the blood vessels are not useful for transplantation.
The cells are now cryopreserved in Humacyte&rsquo;s cell banks, so that when we want to make a batch of regenerative human tissues,
our first step is to take a small file of frozen human cells, and to grow them in the laboratory. We then take these cells and
attach them to a scaffolding that resides inside of a flexible plastic bioreactor. That bioreactor is then filled with a nutritious
medium that has vitamins and glucose and lots of growth factors for these vascular cells. Over a period of two months, what happens
is the cells grow and regenerate a completely functional human neo-artery that has been grown in the laboratory. Importantly, this
new human vessel contains cells and the extracellular matrix that they made, but really does not contain any polymer scaffold because
that scaffold has dissolved. In a final step in our process, Humacyte then exposes the engineered blood vessel to a series of detergent
washes, and what that does is it removes the cells from the tissue. So the final product that gets implanted into patients is actually
an engineered human blood vessel, but that blood vessel is only composed of the extracellular matrix proteins like collagen that
the cells made. Because the cells have been removed, there&rsquo;s really no immunogenic response to the tissue after it&rsquo;s
implanted into patients. Also because the cells are removed, these tissues are non-living and that means they have a shelf life.
Humacyte&rsquo;s current product shelf life is 18 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>19:26</B></TD><TD>If we go to slide 16, you can see the commercial process that we&rsquo;ve built out for manufacturing,
Humacyte &lsquo;s HAVs. Our vessels are grown as modular units with 10 vessel bags attached to each other in a single drawer, and
then 20 of these drawers yoked together into a single bio-manufacturing system. The system is highly automated and highly monitored
and controlled and requires a minimum of human manpower. Our process of eight to 10 weeks for producing engineered arteries is
almost entirely automated and highly controlled and reproducible. Our current facility has the capacity to grow more than 40,000
HAVs per year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">On slide 17, you can see a summary of the key
features of Humacyte &lsquo;s technology. Importantly, homicides tissues are off the shelf, they can be grown and then shipped
to hospitals and stored until a surgeon or a patient needs them. At the time of use the packaging is peeled and the surgeon reaches
in and takes the vessel out of the container, and then can immediately implant it into the patient. There&rsquo;s no donor site
harvesting, no need to strip veins out of patient&rsquo;s legs, or take cells from their bone marrow. There&rsquo;s also been no
evidence of immune response to these tissues. We&rsquo;ve implanted over 400 patients and have never seen immune rejection for
any of these implants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 87.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">Because these vessels become living tissue
over time, they&rsquo;re also highly resistant to infection. We&rsquo;ve seen this, particularly in our trauma patients and in
our dialysis patients who seem to have a very, very low incidence of infection when the HAVs are used to treat their disease, Humacyte&rsquo;s,
HAVs do become living tissue. Cells from the patient migrate into the HAV over time and transform it from a non-living implant
into a living blood vessel that really becomes the patient&rsquo;s own blood vessel. It&rsquo;s regenerative medicine in the truest
sense. Because these are regenerative tissues and they&rsquo;re living, they&rsquo;re also very durable. We&rsquo;ve seen that
these vessels can last five, six, seven, eight years in patients with a variety of different clinical diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>21:49</B></TD><TD>If we go to slide 18, you&rsquo;ll see an image of what&rsquo;s called an angiogram, which is a
photograph of an engineered blood vessel, an HAV, that was implanted into a patient with peripheral arterial disease. These are
CAT scans of that vessel implant. The red tube on the left is the vessel after implantation at four weeks, and on the right that&rsquo;s
the same vessel, but imaged again at six months. As you can see the HAV is bypassing an artery in the leg, which otherwise is completely
occluded. This is a patient who could have suffered amputation had he not had his limb revascularized with the HAV. If we go to
19, you can see an overall summary of our clinical exposure and data. In dialysis access, we have the largest, clinical dataset
with over 350 patients treated. We&rsquo;ve completed three phase two trials, and we have two phase three trials underway. We&rsquo;ve
seen a very low infection rate of the HAV of only 1% per year, and outstanding patency or outstanding functional use of the HAV
for dialysis. In vascular trauma, we have an ongoing phase three trial in collaboration with the US Defense Department. We&rsquo;ve
seen no infections to-date in our trauma patients, and we&rsquo;ve also seen 100% patency, or function of these vessels, in lower
limb implants at 30 days. In peripheral arterial disease, we&rsquo;ve completed two phase 2 trials, one in Europe and one in the
United States. We&rsquo;ve seen no infections of the implants to date, and importantly, we&rsquo;ve seen no amputations of patients
who&rsquo;ve had the HAVs implanted into their lower limbs. We also see outstanding function.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>23:40</B></TD><TD>If you go to slide 20, what you&rsquo;ll see is some examples of how human cells migrate into
the HAV after it&rsquo;s implanted. The image on the left shows human cells that express a protein, that&rsquo;s only expressed
by cells in the walls of our blood vessels. That protein is called alpha actin, and that red stain shows that there are many, many
cells that have migrated into the HAV, and have essentially become vascular wall cells expressing the proteins that we expect to
see and cells in that tissue. This is especially remarkable because at the time of implantation, the HAV had no cells at all. So
if you had stained the HAV before implantation for this Fred protein, you would have seen nothing going on to the other image on
the right-hand side, this is a stain also in red for another cell type called an endothelial cell. Endothelial cells line the insides
of all of our blood vessels, and they are very important for keeping our blood flowing through our arteries. As you can see, there&rsquo;s
a red line of endothelial cells or ECs at the bottom part of the right-hand image. These cells also came from the patient and were
likely derived from STEM cells that were circulating in the patient&rsquo;s bloodstream.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>25:05</B></TD><TD>If we look at dialysis, there&rsquo;s really three methods that patients can use to undergo hemodialysis
when their kidneys fail. On slide 21, you can see these three methods. The most common method, and really the gold standard, is
an arterial venous fistula, where a surgeon directly sews an artery and a vein together in the patient&rsquo;s arm: this can be
a disfiguring operation, as you can see in the upper left. In addition about 40% of the time these operations fail, and the fistula
does not become usable for the patient to use for hemodialysis. A smaller fraction of patients use tunneled catheters for dialysis,
although catheters are very subject to infection and sepsis, and can even lead to patient death in the case of severe infection.
Similarly, synthetic grafts made out of plastics, such as Teflon, are sometimes implanted underneath the skin and use for dialysis
as well, but these graphs are also subject to infection and also are tend to be not very durable, certainly not as durable as AV
fistulas. So that leaves us with a situation where many hemodialysis patients really have very few good options to have long standing
access to their bloodstream so that they can perform dialysis three times a week and maintain life.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">Slide number 22 shows some of the impacts of
the HAV when used for treatment and vascular trauma. When a patient suffers acute injury of a blood vessel, the surgeon has several
options: one, he can strip a vein out of the leg and use that vein to repair the blood vessel in another injured part of the body.
However, that vein stripping is itself injurious, and it also takes time, so during the hour or an hour and a half, while a vein
is being harvested from the patient, the injured blood vessel and the injured limb are not receiving blood flow. This can lead
to increased risk of amputation and infection. To speed things up, sometimes surgeons use plastic graphs such as those made out
of EPTFE or Teflon. However, in contaminated wounds, such as can often happen with car accidents or with industrial accidents,
in contaminated wounds, the Teflon graphs tend to become infected and that can also lead to amputation and other complications.
The potential advantage of the HAV for patients with vascular injury is that the HAV has the advantages of a Teflon graft, because
it can be pulled immediately off the shelf. There&rsquo;s no waiting, there&rsquo;s no harvesting of a vein from another limb.
But, because this is a human tissue that resists infection, we&rsquo;ve seen that when the HAVs are used in traumatic injury, actually
the infection rate has been zero so far. So these are immediately available vessels that function well to restore blood flow, but
do not present a risk of infection for the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>28:16</B></TD><TD>On slide 23, you&rsquo;ll see an example of one of Humacyte&rsquo;s compassionate use cases. Occasionally,
surgeons or patients who have become familiar with Humacyte&rsquo;s technology will reach out and request the special use of the
HAV in a particular compassionate use case. This is an image of a patient who is a 70 year old veteran who was being cared for
at Walter Reed hospital. This patient had had all of his vein from his legs stripped previously in order to have a heart bypass.
He then developed a severe blockage of the artery in his legs and he was facing an amputation. Instead, this patient was able to
receive the HAV, to revascularize his limb, and now two years later, he&rsquo;s doing well and does not have an amputation, and
is walking around and leading his life normally.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">If we go to slide 24, we can see some of the pipeline
opportunities that Humacyte has available. As I mentioned earlier on, Humacyte is using smaller caliber versions of our engineered
vessels as heart bypass graphs in large animal models. This work could have tremendous benefit for the hundreds of thousands of
patients every year who require a heart bypass. Not least of which, because using the Humacyte &lsquo;s vessels off the shelf,
rather than harvesting a vein out of the leg, means that for patients with heart disease, particularly those who are diabetic or
who may be overweight for those patients, avoiding the complications associated with vein harvest can be a very important, clinical
benefit. In addition, unlike veins, which are taken from the patient&rsquo;s leg, which can be different every time, Humacyte&rsquo;s
vessels are uniform and the surgeon always knows what he&rsquo;s getting, so this can be a particular advantage for surgeons when
they&rsquo;re working in the difficult area of revascularizing the heart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>30:14</B></TD><TD>Going to slide 25, you can see some of our early animal data using pancreatic islets to reverse
diabetes in an animal model. The concept here is that for patients with type one diabetes, what they must do is measure their blood
sugar multiple times a day, frequently inject themselves with insulin and/or where automated pumps with needles that extend through
the skin and which have to be carefully monitored and maintained. The alternative to this is to get a pancreas transplant, and
to replace the cells in the pancreas that have died and mean that the patient no longer can make his own insulin. Unfortunately,
pancreas transplant is both dangerous and expensive, and for that reason, there&rsquo;s actually been a falling number of pancreas
transplants in the US year after year. What Humacyte has discovered is that we can combine our engineered vessels with pancreatic
islets. We can take the cells from the pancreas that secrete insulin and consents blood sugar. And we can combine these islets
with an engineered blood vessel when implanted into a small animal with type one diabetes, what we&rsquo;ve shown is that we can
reliably reverse that diabetes over time. Humacyte plans to extend this work into large animal models in the coming year. If we
think about how Humacyte will move forward with commercialization again, the ultimate end markets for some of our many pipeline
products are enormous and easily exceed $100 billion dollars.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">If we go to slide 27, you can see that our
projected peak revenues for some of our different product opportunities going out over the next five to six years. As I mentioned,
approval for vascular trauma is an indication that we expect to obtain in the US in 2023. Shortly thereafter, we would expect to
gain approval in dialysis access, and then several years after that in peripheral arterial disease. Thereafter approvals in products
for the treatment of type one diabetes, noted as pancreas here in this slide, and also coronary artery bypass, grafting abbreviated
as CABG show that the ultimate long-term revenues taken on an international basis could easily be $12 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>32:40</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">If we go to slide 28, you can see that our collaboration with Fresenius is really a global collaboration
to really forward the commercialization and the distribution of Humacyte&rsquo;s products, particularly in dialysis access and
peripheral arterial disease. Fresenius is as a global leader in the delivery of dialysis care, with over 2,500 dialysis centers
in the US treating roughly half of the US patients with end stage kidney failure. Furthermore, Fresenius has a large network of
outpatient surgical facilities that are useful for the placement of access for dialysis patients. With respect to the vascular
trauma indication, Humacyte expects to market that indication itself within the United States. Because the trauma market is a highly
specialized market, there are roughly 190 level one trauma centers in the United States, this allows Fresenius to access these
190 call points with a reasonable size salesforce of only 15 to 20 salespeople. Furthermore, as we develop other longer-term products,
such as treatment for diabetes, and also for coronary artery disease, we anticipate potentially partnering both in the US and internationally
to help to market and distribute these products to these very large markets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.25in"><B>34:01</B></TD><TD>If we go to slide 29, you can see that our anticipated use of proceeds from the combination
of the PIPE investment and also with the funds from the SPAC trust total on the order of $255 million. This will allow us to complete
our filing of our biological licensing applications, or BLA, to the FDA for our first two weeks products, including in vascular
trauma and dialysis access. This will also get us to the point of commercial launch of these products. Furthermore, these funds
will allow us to advance our pipeline in peripheral arterial disease, where we&rsquo;re planning to initiate a phase three trial,
but also in our longer term opportunities such as diabetes and coronary artery disease.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">So that&rsquo;s all we have for today. I&rsquo;ve
really enjoyed speaking with you about the Humacyte opportunity. You know, as the founder of the company, and also as a physician
myself, I&rsquo;m very much looking forward to continuing to see how Humacyte&rsquo;s products benefit patients and help save lives
and limbs. Thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">10</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
